SCHEMBL1595065

SCHEMBL1595065

CC1(C)O[C@@H](C(=O)O)[C@H](C(=O)O)O1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SUCNR1 Q9BXA5 1/20 0.45
MAPK1 P28482 4/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
APLNR P35414 1/20 0.36
GAA P10253 1/20 0.36
PGD P52209 1/20 0.34
KMT2A Q03164 1/20 0.33
CYP3A4 P08684 1/20 0.32
TP53 P04637 1/20 0.32
NFKB1 P19838 1/20 0.32
CYP2C19 P33261 1/20 0.32
THPO P40225 1/20 0.32
STAT6 P42226 1/20 0.32
HIF1A Q16665 1/20 0.32
NPC1 O15118 1/20 0.32
GMNN O75496 1/20 0.32
LMNA P02545 1/20 0.32
MTOR P42345 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1595064 1.00 SUCNR1 (0.45) SUCNR1MAPK1NPSR1KDM4EALDH1A1
SCHEMBL27159744 1.00 SUCNR1 (0.45) SUCNR1MAPK1NPSR1KDM4EALDH1A1
SCHEMBL10473227 1.00 SUCNR1 (0.45) SUCNR1MAPK1NPSR1KDM4EALDH1A1
SCHEMBL1727954 1.00 SUCNR1 (0.45) SUCNR1MAPK1NPSR1KDM4EALDH1A1
SCHEMBL18219198 0.90 SUCNR1 (0.38) SUCNR1MAPK1NPSR1KDM4EALDH1A1
SCHEMBL18219558 0.90 SUCNR1 (0.38) SUCNR1MAPK1NPSR1KDM4EALDH1A1
SCHEMBL13997318 0.87 SUCNR1 (0.39) SUCNR1MAPK1NPSR1KDM4EALDH1A1
SCHEMBL26678742 0.87 SUCNR1 (0.39) SUCNR1MAPK1NPSR1KDM4EALDH1A1
SCHEMBL14007051 0.87 SUCNR1 (0.39) SUCNR1MAPK1NPSR1KDM4EALDH1A1
SCHEMBL5048000 0.87 SUCNR1 (0.39) SUCNR1MAPK1NPSR1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190008991-A1 MALODOR REDUCTION COMPOSITIONS THE PROCTER & GAMBLE COMPANY 2019-01-10 US claimed
EP-3424539-A1 MALODOR REDUCTION COMPOSITIONS The Procter & Gamble Company (US) 2019-01-09 EP claimed
US-6143379-A Polymer laminates having increased hiding power CLARIANT GMBH (DE) 2000-11-07 US claimed
EP-3704120-B1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC (US) 2024-03-06 EP disclosed
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS JUBILANT EPISCRIBE LLC 2021-12-02 US disclosed
US-11168097-B2 Photochemical methods of making cyclobutane boronates and related compounds WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2021-11-09 US disclosed
US-11020386-B2 Methods and compositions for preventing opioid abuse ALBANY MOLECULAR RESEARCH, INC. (US) 2021-06-01 US disclosed
US-11020386-B2 Methods and compositions for preventing opioid abuse ALBANY MOLECULAR RESEARCH, INC. (US) 2021-06-01 US disclosed
EP-3704120-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS Jubilant Episcribe LLC (US) 2020-09-09 EP disclosed
US-10765648-B2 iNKT cell modulators and methods of using the same LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) 2020-09-08 US disclosed
CN-111542523-A Heterocyclic compounds as PRMT5 inhibitors 朱比连特埃皮斯科瑞有限责任公司 2020-08-14 CN disclosed
US-6143379-A Polymer laminates having increased hiding power CLARIANT GMBH (DE) 2000-11-07 US disclosed
US-5613494-A ULTRASONIC CONTRAST AGENT, MICROPARTICLES CONTAINING A GAS HOECHST AKTIENGESELLSCHAFT (DE) 1997-03-25 US disclosed
US-5505784-A Polycondensates which contain tartaric acid derivatives, processes for their preparation and use thereof HOECHST AKTIENGESELLSCHAFT (DE) 1996-04-09 US disclosed
US-5391696-A Biodegradable polyesters and polyamides for sustained drug delivery and as ultrasonic contrast agents in medical diagnosis, particularly blood circulation of the heart HOECHST AKTIENGESELLSCHAFT (DE) 1995-02-21 US disclosed
US-5142099-A Hemicaronic aldehyde intermediates ROUSSEL UCLAF (FR) 1992-08-25 US disclosed
US-5047557-A Complexes having optically active ligands, a process for their preparation and their use CIBA-GEIGY CORPORATION (US) 1991-09-10 US disclosed
US-4996349-A Reducing dioxolane diester to dialdehyde, adding ester using organic phosphorus compound, reacting with gem-dimethylcyclo-propanation reagent, hydrolyzing, cleaving ROUSSEL UCLAF (FR) 1991-02-26 US disclosed
US-4942227-A ANTITUMOR AGENTS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 1990-07-17 US disclosed
EP-0305289-A1 Enantioselective process for preparing derivatives of trans- or cis-hemicaronaldehyde, and intermediates obtained ROUSSEL-UCLAF (FR) 1989-03-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10765648-B2 iNKT cell modulators and methods of using the same PBK, NFATC1, UGCG SUCNR1 2721/4885MAPK1 4336/4885NPSR1 2394/4885
US-11020386-B2 Methods and compositions for preventing opioid abuse OPRM1, OPRK1, OPRD1 SUCNR1 1109/4885MAPK1 4617/4885NPSR1 92/4885
US-11168097-B2 Photochemical methods of making cyclobutane boronates and related compounds BLVRB, CYP11B2, CYP11B1 SUCNR1 747/4885MAPK1 1889/4885NPSR1 2133/4885
US-20210371431-A1 HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT3 SUCNR1 1854/4885MAPK1 576/4885NPSR1 4120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.